Objective: To assess the efficacy and safety of CT-guided iodine-125 seeds in the treatment of intracranial malignancies under control of target and dose. Methods: From November 2003 to May 2016, with the clinical data of 412 operations on 310 patients in 12 hospitals in the past 14 years, this study analyzed the method of CT guided iodine-125 particles brachytherapy in the treatment of intracranial malignant tumors and evaluated the efficacy and complications. Stratification analysis of intracranial malignant tumors was performed. Results: Overall survival (OS) of patients with single brain metastases, low-grade glioma, high-grade gliomas, recurrence after surgery, recurrence after radiotherapy and others were 19, 67, 41, 26, 23, 46 months respectively.And the progression free time (PFS) of patients with single brain metastases, low-grade glioma, high-grade gliomas, recurrence after surgery, recurrence after radiotherapy and others were 19, 42, 6, 9, 11, 12 months respectively.Various complications were observed with a relatively low incidence of 10.4%.Three cases deceased at an interval of 7-45 days after treatment. Conclusions: For patients with intracranial malignancies, iodine-125 seeds brachytherapy could achieve a satisfactory treatment efficacy with tolerated complications.Iodine-125 seeds brachytherapy may act as a first-line regimen.
目的： 再次评价靶区和剂量控制下(125)I粒子治疗颅内恶性肿瘤的疗效和并发症。 方法： 回顾分析2003年11月—2016年5月青岛大学附属医院、山东省滕州市中心人民医院、山东省邹平中医院等12家医院310例颅内恶性肿瘤患者412次手术的临床资料，分析靶区和剂量控制下(125)I粒子治疗颅内恶性肿瘤的技术，评价疗效和并发症。对颅内恶性肿瘤进行分层研究，行靶区和剂量控制下(125)I粒子治疗。 结果： 单发脑转移瘤、低级别胶质瘤、高级别胶质瘤、手术后复发、放疗后复发、其他(脑膜瘤、垂体瘤等)中位生存期分别是19、67、41、26、23、46个月；中位无进展生存时间分别是19、42、6、9、11、12个月。并发症种类多，发生率低，总并发症发生率10.4%；术后7～45 d死亡3例。 结论： 靶区和剂量控制下(125)I粒子治疗颅内恶性肿瘤可以取得较好的疗效，而并发症较低，与外科切除、外放射治疗各具特点，应该进一步研究，并形成临床路径。.
Keywords: Brachytherapy; Brain neoplasms; Iodine 125; Radiotherapy dosage.